AI in Digital Genome Market

AI in Digital Genome Market Overview

The global AI in digital genome market size, valued at USD 655 million in 2024, is projected to reach USD 1,186 million in 2025 and USD 45,461 million by 2035, representing a CAGR of 44% during the forecast period.

To learn more about this report, request a free sample copy

AI in Digital Genome Market: In Summary

• The global AI in digital genome market is projected to reach USD 45,461 million by 2035. This significant growth is fueled by the rising prevalence of chronic diseases and genetic disorders, which necessitates the development of precision medicine.
• The ability of AI to transform complex genomic data into actionable insights for early disease detection, drug discovery, and understanding disease mechanisms is likely to drive the demand for AI in digital genome.
• The software segment currently leads the market and is expected to maintain its dominance, growing at the fastest CAGR. This is due to the increasing adoption of AI-based genome sequencing software for storing, handling, and processing unstructured genomic data, including epigenomics, proteomics, and genomic sequences.
• Machine learning holds 60% share of the AI in digital genome market. Its ability to interpret complex genomic data and analyze it in real-time, including identifying non-obvious patterns, makes it crucial for genomic analysis. This segment is also projected to expand at a higher CAGR.
• Pharmaceutical and biotechnology companies currently lead the market with a 55% share, owing to the rising use of AI for genomic data analysis, novel drug target identification, and validating complex biological pathways. Research organizations are expected to grow at a higher CAGR, driven by increasing research in genomics, metabolomics, and transcriptomics, all of which require robust AI tools for data interpretation.
• North America holds the largest share of the AI in Digital Genome market. This dominance is due to ongoing technological innovation and expanding genomic research in the region. The Asia-Pacific market is projected to experience the highest CAGR, propelled by a growing focus on personalized treatments based on genetic makeup and the rising incidence of chronic diseases like cancer and cardiovascular diseases.
• Recent strategic initiatives demonstrate the dynamic nature of this market. For instance, MGI Tech's (China) collaborated with GenePowerRx (India) to revolutionize predictive healthcare and precision oncology medicine through sequencing and AI-powered genome analytical tools.
• AI platforms are increasingly integrating genomic data with metabolomics, proteomics, and other 'omics' data to gain comprehensive biological insights. Decentralized testing and subscription-based models are some of the promising trends that are shaping the industrial growth in this region.

AI in Digital Genome Market Introduction

Given by the growing shift from one-size fit approach to personalized treatment, digital genomics has gained a significant attention. Digital genome acts as a genetic blueprint of a patient. It comprises of complete information such as gene, genetic variation, regulatory element, genome sequence, and other biological information that are useful to develop personalized drugs. By integrating artificial intelligence (AI) in digital genomes, research can analyze and interpret genomic data, their role in diseases and provide a tailored treatment to meet individual patient’s requirement with utmost accuracy.

AI in digital genome functions as an advanced analytical tool to transform complex data into actionable format, making it an invaluable tool for early disease detection, drug discovery, and understanding disease mechanism. This shift towards predictive analysis and acceptance of digital health tools for disease monitoring / management has made this industry progressive in the upcoming years. Moreover, the growing concern of chronic conditions, such as cardiovascular diseases, metabolic disorders and cancer has further increased the demand for AI in digital genome.

With increasing demand across healthcare and pharmaceutical industries, several market players are actively exploring new possibilities for innovations in this field. Market players, such as MGI Tech (China), Illumina (US), and NVIDIA (US) are leveraging partnerships for developing AI based digital genome technologies. For instance, in June 2025, MGI Tech (China) signed a strategic collaboration with GenePowerRx (India) to revolutionize the predictive healthcare and precision medicine landscape through cutting-edge sequencing and AI-powered genome analytical tools. Owing to the rising need for advanced genome analytical tools and active interest of industrial players for innovation, we believe that AI in digital genome market will continue to grow at a substantial pace in the future.

AI in Digital Genome Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 1,186 Million
Market Size 2035	USD 45,461 Million
CAGR (Till 2035)	44%

One of the key objectives of the AI in digital genome market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global AI in digital genome market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of offering, type of technology, type of functionality, application area, end user, geographical regions, and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry's evolution.

Case Study: How Tempus Precision Healthcare System (US) Harnessing the Power of AI?

AI in digital genome has completely revolutionized personal medicine by offering detailed insight to genome for customizing therapies. By examining patients’ genomic data, artificial intelligence can recommend appropriate treatment, specifically in oncology.

One standout real-world example is Tempus Precision Healthcare System (US). Tempus uses advanced AI algorithms to interpret genomic and clinical data, enabling the development of tailored cancer therapies. Its technology analyzes the individual genetic profiles of patients, identifying effective treatment paths that may not be obvious through traditional methods.

This integration of AI not only leads to more effective therapies but also supports faster and better-informed decision-making for clinicians. Patients benefit from therapies matched specifically to their genetic makeup, which can result in improved treatment outcomes and higher survival rates.

Recent Developments in AI in Digital Genome Market

Several recent developments in the field of artificial intelligence in digital genome have occurred and we have outlined some of these below:

• In May 2025, QIAGEN (Germany) announced that it has signed a definitive agreement with Genoox (US) for USD 70 million. Under this acquisition deal, Genoox’s (US) flagship cloud-based community platform will be added to QIAGEN Digital Insights (QDI) portfolio to strengthen the leading of QIAGEN in genetic interpretation for clinical genomics applications.
• In May 2025, Betamek Berhad (Malaysia) signed a partnership agreement with SiGenex Global Holding (Singapore) to conjointly development artificial intelligence genomics diagnostic and sequencing solutions.
• In February 2025, DNAstack successfully launched Canadian Platform for AI in Health (new USD17.5 million project) for the expansion of software to make AI-powered discoveries in genomics and healthcare.
• In January 2025, NVIDIA (US) announced its partnership with Illumina (US) at the 43rd Annual J.P. Morgan Healthcare Conference. Under this partnership, the company will implement AI technologies and genomics to analyze and interpret multi-omics data in clinical research, drug discovery and human health.

AI in Digital Genome Market Segmentation Insights

The market report presents an in-depth analysis of AI in digital genome technologies developers who are currently active across various segments of the industry as mentioned below:

AI in Digital Genome Market: Market Segmentation

Market Segmentations	Details
Type of Offering	Software Services
Type of Technology	Machine Learning Computer Vision
Type of Functionality	Genome Sequencing Gene Editing
Application Area	Diagnosis Drug Discovery and Development Precision Medicine Agriculture & Animal Research Other Applications
End User	Pharmaceutical and Biotechnology Companies Research Organizations
Geographical Regions	North America Europe Asia-Pacific Middle East and North Africa Latin America
Market in North America	US Canada Mexico
Market in Europe	France Germany Italy Spain UK Rest of Europe
Market in Asia-Pacific	China India Japan South Korea New Zealand Rest of the Asia-Pacific
Market in Middle East & Africa	Egypt Iran Iraq Israel Saudi Arabia South Africa United Arab Emirates
Market in Latin America	Argentina Brazil

Industry Experts on AI in Digital Genome Market

Experts suggest that AI in genomics is a billion-dollar opportunity. The integration of AI with genomics unlocks new possibilities to identify the patterns of diseases that are still hidden due to the implementation of traditional approach.

"AI is extensively used in genomics to expand its application potential and increase the speed and accuracy at which vast amounts of genomic data are analyzed," said Neeraja V, (Senior Analyst at the Consultancy Everest Group). AI has demonstrated the ability to analyze and identify genetic variations and detect patterns and protein structures, she added. AI also enables multiomic data analysis beyond genomics for integrated metabolomic, proteomic, transcriptomic and epigenomic analysis.

AI in Digital Genome Market Share Insight

Market Share by Type of Offering: Which Type of Offering Dominate the Market?

• The global market is categorized based on the type of offering into software and service. Based on the AI in digital genome market forecast, the software segment is set to lead to the market and this segment will continue to maintain its leadership. This dominance can be ascribed by the increasing acceptance of AI-based genome sequencing software to store, handle and proceed unstructured genomic data.
• It is important to mention here that the software segment will continue to grow at the fastest CAGR during the forecast period. The ability to explore vast amounts of data generated through epigenomics, proteomics, and genomic sequence will continue to bolster the demand of cloud-based genomic AI in healthcare and pharmaceutical industry.

Market Share by Type of Technology: Which Technology Will Take the Lead in the Future?

• This segment reflects the sub-division of global market across machine learning, and computer vision. According to the AI in digital genome market analysis, the machine learning segment is taking the lead by holding 60% of the market share. Notably, machine learning in genomics plays a significant role in interpreting complex structure of genomic data and analyzing in real-time.
• It is worth mentioning that machine learning algorithms, including deep learning for genomics excels in identifying the non-obvious patterns within genomic data, which is challenging to explore with a traditional approach. Owing to its significance, this segment will continue to expand at a higher CAGR during the forecast period.

Market Share by Type of Functionality: Will Genome Sequencing Continue to Dominate the Market?

• The global market is sub-divided across different types of functionalities, such as genome sequencing and gene editing. Among these, genome sequencing is dominating by occupying highest AI in digital genome market share. This dominance reflects from the increasing focus on the genome research for designing personalized drugs. AI in digital genomics plays a significant role in interpreting data generated from genome sequencing technology.
• Notably, the AI based genome interpretation can offer diverse opportunities to explore unstructured data from DNA sequencing, epigenomics, and proteomics. Driven by the dependency on AI based tools for genome analysis, this segment will continue to grow at a higher CAGR during the forecast period.

Market Share by Application Area: How AI in Drug Discovery Genomics is Dominating the Market?

• This segment highlights the distribution of global market across different application areas, such as diagnosis, drug discovery and development, precision medicine, agriculture & animal research, and other applications. According to the projection, the drug discovery and development segment holds the highest share of AI in digital genome market size. This can be ascribed by the growing adoption of AI in genome analytics for the research and development of targeted drugs.
• It is important to note that precision medicine is likely to grow at the fastest CAGR during the forecast period. The integration of AI for precision medicine helps to gain valuable insight on whole genome, and underlying causes of disease mechanism. Moreover, the increasing approach of multi-omics beyond genomics analysis, such as metabolomics, and transcriptomics is underscoring the need of AI based software / platform for data interpretation.

Market Share by End User: Will Pharmaceutical and Biotechnology Companies Continue to Lead the Market?

• Based on the end user, the global market is bifurcated into pharmaceutical and biotechnology companies, and research organizations. Currently, the pharmaceutical and biotechnology companies’ segment is dominating the industry by holding 55% share of the AI in digital genome market. This dominance is due to the rising usage of artificial intelligence for genomic data analysis, finding novel drug targets and validate complex biological pathways and disease mechanism to develop personalized drugs.
• It is important to highlight that the research organization’s segment is likely to grow at a higher CAGR during the forecast period. This lucrative growth is due to the rising research on genomics, metabolomics and transcriptomics. The complex generated data through omics study requires robust tools like AI in omics data analysis for data interpretation.

Market Share by Geographical Regions: Why is North America Holding Highest Share of the Market?

• The global market is distributed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. According to the AI in digital genome market forecast, North America is holding maximum share of the market, and the trend is likely to remain unchanged in the future. Several factors, such as rising technological innovations, expanding research on genomics, and high demand for personalized drugs are accelerating the demand for AI technology in this region.
• In Asia-Pacific, the market for AI in digital genome is likely to grow at a higher CAGR during the forecast period. The growing focus on personalized treatment to meet individual patient’s requirement based on genetic makeup and rising chronic diseases (cancer, neurological disorders and cardiovascular diseases) are driving the requirement of AI based genome sequencing technologies.

AI in Digital Genome Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Available
Key AI in Digital Genome Companies Profiled	BenevolentAl (UK) Deep Genomics (Canada) Fabric Genomics (US) IBM (US) Microsoft (US) MolecularMatch (US) NVIDIA (US) PrecisionLife (UK) SOPHIA GENETICS (Switzerland) Verge Genomics (US) (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

AI in Digital Genome Market Key Takeaways

The "AI in Digital Genome Market Report: Industry Trends and Global Forecasts, till 2035" market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for market players. The market research report lays emphasis on the AI in digital genome technologies / solutions that are being developed. Key takeaways of the market report are briefly discussed below.

Market Competitive Landscape: Competitive Landscape and Key Players in AI In Digital Genome Market

The market for AI in digital genome is highly competitive, characterized by the presence of established technology giants and new entrants. Notably, the market players, such as NVIDIA (US), Microsoft (US), and SoPHiA GENETICS (Switzerland) are highly focused on the development of advanced genome AI platforms, deep learning in genomes and cloud-based AI solutions for data analysis.

Furthermore, the market players are undertaking strategic initiatives, followed by technological innovations, collaborations, acquisition, and partnerships. Some of the strategic initiatives are listed below.

• In April 2025, GeneDx (US) acquired Fabric Genomics (US) to enable decentralized AI-powered genomic testing at global scale.
• In January 2025, Microsoft (US) chairman and CEO Satya Nadella announced cloud and AI led strategic partnerships with the Government of India and market players from across Indian industrial sector.

With consistent efforts toward technological innovations in this field, we believe that AI in digital genome market will remain competitive during the forecast period.

Market Drivers: What are the Key Drivers for Growth in AI in Digital Genome Market?

The AI in digital genome industry market growth is propelled by several factors that are listed below:

Increasing Prevalence of Chronic Disease and Genetic Disorders

With increasing concern of chronic diseases and genetic disorders, it is driving the requirement for precision medicine. Notably, the development of precision medicine require integrating omics data generated from next generation sequencing and clinical data records, such as electronic health records. Moreover, the approach also required the discovery of biomarkers for the development of personalized medicine, which further necessitated the demand for AI for biomarker discovery for data analysis.

Growing Regulatory Support for AI Integration in Genomics

It is interesting to highlight here that regulatory agencies, such as the USFDA and the EMA have established guidelines for the acceptance of AI technologies for genomic testing regulation as Class II medical devices. This support from the regulatory agencies demonstrates the efficacy and safety of using genome AI technologies. Driven by the regulatory support, there will be surge in the integration of next-generation sequencing with artificial intelligence platforms for real-time genomic interpretation.

Market Challenges: What Challenges Affect the Adoption of AI in Digital Genome Solutions?

Despite promising growth, several factors may impede the market progress that are listed below:

Challenges in AI-Powered Digital Genome Data Security and Regulation

Data security is one of the significant challenges that hinder market progress. Notably, genomic data is highly sensitive and data interpretation through cloud-based AI platforms raises data privacy concerns. In order to ensure data security, industrial players are required to follow General Data Protection Regulation (GDPR) and other cybersecurity regulations.

Technology Integration and Computational Challenges

It is important to highlight here that the integration of AI genomics platforms with existing healthcare IT system is challenging. Moreover, many healthcare organizations are operating conventional legacy systems that are not compatible with modernized AI based genomics platforms. These complexities may limit the adoption across healthcare industry.

Future Trends: What are the Emerging Trends in Cloud-Based and Explainable AI for Genomics?

Several market trends are shaping industrial growth, offering enormous opportunities to industrial players. Some of the potential trends are listed below:

Multi-Omics Integration: How Does AI Improve Genome Sequencing and Interpretation?

Notably, the AI based platforms are increasingly being integrated with genomic data with metabolomics, proteomics, and omics data to gain comprehensive biological insights. Additionally, the integration of AI with genome sequencing technologies are enabling more precision in genome data analysis that further helps to develop tailored drugs. Moreover, AI can also help to identify multi-omics biomarker signatures, such as genetic variants, protein markers, gene expression levels, and metabolites that indicate disease progression, risk and helpful to identify drug response.

Decentralization Testing and Subscription-Based Models: What Technological Advancements are Shaping AI in Digital Genome Market?

The growing trend towards decentralized genomic testing is likely to propel market growth in the future. Notably, the decentralized genome testing allows the pharmaceutical and healthcare industry to perform on-site sequence while accessing the centralized AI interpretation platforms. This decentralized testing will help industrial players to develop tailored drugs and treatment to enhance patient outcomes. Additionally, several AI in digital genome industry players are developing subscription-based genomics analysis services model, which eases the financial burden from companies for leveraging cost-effective genome AI platforms for data analysis.

AI in Digital Genome Market Size Analysis: What Trends are Shaping AI in Digital Genome Market?

In 2025, the AI in digital genome market is valued at USD 1,186 million and is projected to reach USD 45,461 million by 2035. This lucrative growth is driven by the increasing shift towards personalized medicine and adoption of digital health technologies. Presently, market players are expanding their product portfolio / services to meet with global demand, which is further likely to expand the market.

AI in Digital Genome Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the AI in diagnostics industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary
• Regulatory Scenario
• Comprehensive Database of Leading Players
• Competitive Landscape
• Porter’s Five Forces Analysis
• Company Competitiveness Analysis
• Startup Ecosystem in the AI in Digital Genome Market
• Company Profiles
• Partnerships and Collaborations
• Market Forecast and Opportunity Analysis
• Adjacent Market Analysis
• Key Winning Strategies
• Value Chain Analysis

Glossary

• Genomics: The study of an organism's complete set of DNA, including all genes and non-coding sequences.
• CRISPR: It is a revolutionary gene-editing technology that allows precise modifications to DNA sequences.
• Precision Medicine: This is a form of medical treatment tailored to individual patient characteristics, including genetic makeup, lifestyle, and environment.
• Biomarkers: It is a measurable biological indicators that can be used to diagnose diseases, predict treatment responses, or assess disease progression.
• Machine Learning: This refers to the subset of AI that enables computers to learn and improve from experience without being explicitly programmed.
• Deep Learning: It is an advanced form of machine learning that uses neural networks to model complex patterns in data.

From the Author’s Desk

Author’s View on AI in Digital Genome Market

The AI in digital genome market is poised for extraordinary growth, driven by technological convergence, declining sequencing costs, and the escalating demand for precision medicine. While challenges related to data privacy, regulatory clarity, and data standardization exist, the immense potential for accelerating scientific discovery, revolutionizing drug development, and personalizing healthcare far outweighs these hurdles, making this market investable for the long term.

Customization Opportunities

At Roots Analysis, we genuinely care about your success and understand that your business requirements are unique. While our market research reports provide valuable insights, we recognize that they might not cover every aspect you need to make well-informed strategic decisions. To account for that, we offer 15% free report customization tailored to your specific needs. Whether you require additional quantitative analysis, qualitative insights, or any other information related to the electric vehicles market, reach out to us today at support@rootsanalysis.com